A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent Clostridioides difficile infection
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anti-infective Therapy"
DOI: 10.1080/14787210.2023.2171986
Abstract: ABSTRACT Introduction Clostridiodes difficile infection (CDI) is a life-threatening illness that has been labelled as an urgent threat by the Centers for Disease prevention (CDC). Areas Covered RBX2660, a live biotherapeutic product offers a very… read more here.
Keywords: live biotherapeutic; infection; rbx2660; biotherapeutic product ... See more keywords
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "BMC Infectious Diseases"
DOI: 10.1186/s12879-022-07256-y
Abstract: Background Effective treatment options for recurrent Clostridioides difficile infection (rCDI) are limited, with high recurrence rates associated with the current standard of care. Herein we report results from an open-label Phase 2 trial to evaluate… read more here.
Keywords: recurrence; trial; treatment; label phase ... See more keywords